Products

SKOUT system
Iterative Health
Gastroenterology AI
Iterative Health's SKOUT system is an FDA-cleared AI-assisted polyp detection tool for gastroenterologists, designed to enhance the identification of colorectal polyps during colonoscopies and improve colorectal cancer screening outcomes.

See all 1 product →

About Iterative Health

Iterative Health is a healthcare technology and services company dedicated to accelerating clinical research and improving patient outcomes through the application of artificial intelligence. For physicians, this translates into advanced tools designed to enhance diagnostic accuracy and streamline clinical trial participation, particularly within gastroenterology. The company’s platform leverages machine learning and computer vision to interpret endoscopic images and other clinical data, providing more consistent, accurate, and individualized disease assessments. This technology aids clinicians in better diagnosing gastrointestinal disorders, standardizing disease severity characterization, and optimizing patient management.

A key offering, the AI-powered SKOUT system, assists gastroenterologists in real-time polyp detection during colonoscopies, aiming to improve screening and surveillance for colorectal cancer. Beyond diagnostic support, Iterative Health operates a global, performance-driven site network embedded within community care settings. This network connects pharmaceutical sponsors with high-performing research sites, facilitating faster and more predictable clinical trials across therapeutic areas including Gastroenterology, Hepatology, Obesity, and Cardiology. By streamlining trial execution and expanding patient access to novel therapeutics, Iterative Health aims to accelerate the delivery of life-changing therapies to patients who need them most.

Focus Areas

AI-driven precision medicine gastroenterology hepatology inflammatory bowel disease (IBD) colorectal cancer screening clinical trial acceleration computer vision machine learning endoscopic scoring systems site network

Business Intelligence

Key InvestorsAlumni Ventures, Clearlake Capital Group, Insight Partners, Koru Capital, Reform Ventures, Obvious Ventures, Johnson & Johnson Innovation - JJDC Inc., Eli Lilly
PartnershipsGI Alliance, One GI, US Heart & Vascular (USHV), Gastro Health
AcquisitionsClinical Research Strategy Group, Precision Research
TechnologyAI-powered platform, machine learning, computer vision, AI Recruitment (AI-R), SKOUT (polyp detection system), AI Documentation (in development)
FDA Clearances1 cleared products (estimated)

What Physicians Need to Know

Specialization
Iterative Health specializes in AI-driven precision medicine across gastroenterology, hepatology, inflammatory bowel disease (IBD), and colorectal cancer screening. They are also deeply involved in clinical trial acceleration, leveraging computer vision and machine learning for endoscopic scoring systems and building a robust site network.
Clinical Trial Acceleration
They power a performance-driven site network that accelerates GI, Hepatology, Obesity, and Cardiology trials, aiming for faster site activation and increased patient enrollments. Their AI Recruitment (AI-R) technology streamlines patient identification and recruitment for IBD clinical trials, demonstrating a 40% uplift in patient randomizations.
AI-Powered Diagnostics & Endoscopy
Iterative Health utilizes advanced machine learning and computer vision to interpret endoscopic images and videos, enhancing the detection, annotation, and disease scoring of GI-related conditions. Their SKOUTu2122 system, an FDA-cleared real-time computer-aided polyp detection device, has shown a 27% relative increase in adenoma detection during colonoscopies. They also have AI Documentation in development to provide detailed and accurate procedure documentation.
Therapeutic Focus
While their core AI applications are in GI and Hepatology, particularly for IBD and colorectal cancer, their site network also supports clinical trials in Obesity and Cardiology.
Physician Tip

For physicians, Iterative Health offers several key advantages. Their AI-powered tools, such as SKOUTu2122 for polyp detection and AI-R for patient recruitment, can significantly improve diagnostic accuracy and consistency in endoscopic assessments, reducing inter-observer variability in disease scoring for conditions like IBD. This leads to more objective and standardized data, which is crucial for both clinical practice and research. Physicians can leverage their site network and operational support to integrate clinical research as a profitable ancillary service, providing patients with access to novel therapeutics without leaving their communities. The platform also aims to reduce administrative burden through automated documentation and streamlined patient screening, allowing physicians to focus more on patient care. Furthermore, Iterative Health provides comprehensive training and professional development through 'Iterative U' for research teams, ensuring high-quality trial execution.

Iterative Health's technology is designed to integrate with existing endoscopy systems and can combine EHR and video data to generate real-world evidence. They partner with leading provider networks like GI Alliance and One GI to expand access to clinical trials across community-based practices, laying the groundwork for future AI solution integrations into GI practices.

Products by Iterative Health

1 product in the directory

SKOUT system
Iterative Health
Gastroenterology AI
Iterative Health's SKOUT system is an FDA-cleared AI-assisted polyp detection tool for gastroenterologists, designed to enhance the identification of colorectal polyps during colonoscopies and improve colorectal cancer screening outcomes.

What the Web Says

Iterative Health is a healthcare technology company that uses AI to accelerate clinical research and improve patient outcomes, particularly in gastroenterology. They focus on streamlining clinical trials, expanding patient access, and augmenting clinical decision-making. The company has received positive feedback for its mission-driven culture, competitive compensation, and comprehensive benefits. However, some employees note the fast-paced, startup-like environment can lead to shifting priorities and intense workloads.

Overall: Mixed

Strengths

  • Mission-driven work with a focus on transforming gastroenterology care and accelerating clinical research using AI.
  • Opportunity to make a significant impact and be part of building something new.
  • Competitive compensation and comprehensive benefits, including substantial employer-paid health coverage and 401(k) match.
  • Hires outstanding people and fosters a culture of strong teamwork.
  • Work is interesting and evolving, with promising growth opportunities.
  • Good technology for employees, cool office, and stocked kitchen.

Limitations

  • Fast-moving environment with shifting priorities and many moving parts, which can be overwhelming.
  • Heavy workloads and intensity are noted as recurring realities.
  • Some references to periods of layoff anxiety and volatility.
  • Processes are still maturing, which can be frustrating for those expecting stable, standardized operations.
  • Potential for uneven experiences depending on the team due to team-to-team variability.
  • Feels like a startup, which can mean lots of moving parts and constantly changing priorities.

Based on reviews from: Indeed.com, Built In, Iterative Health Website

Last updated: 2026-07-18

Videos

News, demos, and interviews about Iterative Health.

Loading videos...

Videos load interactively. If none appear, search YouTube for Iterative Health →

View all on YouTube

Press & Coverage

Clinical Trials Arena
Iterative Health banks $77m to level up AI-driven clinical research tech
Iterative Health secured $77 million in Series C funding, led by Google Ventures and Intrepid Growth Partners, to expand its AI-powered clinical research network into new therapeutic areas like cardiology and obesity. The company aims to address recruitment challenges in clinical trials by providing centralized access to diverse patient populations.
2026-05
TAMradar Funding Rounds Signals
Iterative Health Raises $77M Series C for AI Trial Network - TAMradar Funding Rounds Signals
Iterative Health, a Boston-based company focusing on clinical research in GI, hepatology, obesity, and cardiology, raised $77 million in Series C funding, achieving unicorn status with a valuation of approximately $1.3 billion. The funding will support expansion into new therapeutic areas and enhance its AI-powered patient pre-screening and site activation capabilities.
2026-04
Iterative Health (Business Wire)
Iterative Health Closes $77 Million Series C to Accelerate the Future of Clinical Research
Iterative Health announced the close of a $77 million Series C financing round, led by Intrepid Growth Partners and GV (Google Ventures), to accelerate clinical research and expand its multispecialty clinical research network. The funding will support expansion into cardiology and obesity, building on existing collaborations and geographic growth.
2026-04
Iterative Health (Business Wire)
Iterative Health and Gastroenterology Associates of New Jersey Partner to Expand Patient Access to Advanced GI Research
Iterative Health announced a strategic partnership with Gastroenterology Associates of New Jersey (GANJ) to integrate clinical research into community GI care across New Jersey, establishing two new research sites. This collaboration aims to expand patient access to advanced GI research and leverage Iterative Health's operational model and AI-powered innovation.
2026-07
Iterative Health (Business Wire)
Iterative Health Acquires Cardiology Sites from NextStage Clinical Research
Iterative Health acquired three cardiology sites from NextStage Clinical Research in Texas, expanding its cardiovascular research capabilities and deepening its reach into a high-need therapeutic area. This acquisition aligns with Iterative Health's model of embedding research within community care settings to improve patient access to innovative therapies.
2026-05
Iterative Health (Journal of Crohn's and Colitis)
New Journal Article in the Journal of Crohn's and Colitis: Accelerating Enrollment in Phase 2 and 3 IBD Trials Through the Iterative Health Site Network
A new peer-reviewed article in the Journal of Crohn's and Colitis highlights how Iterative Health's site network accelerates enrollment in Phase 2 and 3 IBD trials. The article addresses recruitment challenges in inflammatory bowel disease research.
2026-02
Iterative Health (Journal of Crohn's and Colitis)
New Journal Article in the Journal of Crohn's and Colitis: AI-Enabled Endoscopy and Histology Reveal Novel Insights into Ulcerative Colitis
A peer-reviewed journal article in the Journal of Crohn's and Colitis discusses how AI-enabled endoscopy and histology are revealing novel insights into ulcerative colitis. Iterative Health is leveraging these AI-driven innovations to advance IBD research.
2026-02
Business Wire
Iterative Health and US Heart & Vascular Enter Strategic Partnership to Advance Community-Based Cardiovascular Research
Iterative Health and US Heart & Vascular announced a strategic partnership to advance community-based cardiovascular research. USHV research sites will join Iterative Health's global site network, expanding Iterative Health's multispecialty focus into cardiology.
2026-04

Frequently Asked Questions

Iterative Health utilizes advanced machine learning and computer vision to interpret endoscopic images and other clinical data, providing enhanced capabilities for the detection, annotation, disease scoring, and treatment of gastrointestinal and hepatological conditions. This AI-driven approach aims to standardize disease severity characterization, particularly in inflammatory bowel disease (IBD), and improve the accuracy of colorectal cancer screenings.
Iterative Health offers AI-powered solutions like SKOUT, an FDA-cleared device for real-time polyp detection during colonoscopies, which has shown to significantly improve adenoma detection. For IBD, they provide AI-enabled Endoscopic Score (AI-ES) technology to automate and standardize the scoring of endoscopic inflammation severity, aiding in more objective disease assessment and clinical trial recruitment.
Iterative Health accelerates clinical trials by powering a global site network that streamlines operations, improves patient recruitment through AI Recruitment (AIR) technology, and reduces operational burden for research sites. This network has demonstrated faster site activation and increased patient enrollment rates, ultimately aiming to bring life-changing therapies to market more quickly.
Iterative Health maintains a compliance program aligned with HHS OIG guidance and the PhRMA Code, striving for substantial compliance with relevant regulations like California Health & Safety Code. They prioritize regulatory compliance and data privacy, including adherence to GDPR, HIPAA, and SOC 2 Type II audit preparation, ensuring their clinical trial optimization solutions meet stringent healthcare and data privacy requirements.
Iterative Health provides comprehensive support to its partner sites, including end-to-end operational assistance for study start-up, regulatory management, patient enrollment, and financial and legal support. They also foster strategic partnerships with leading provider networks like GI Alliance, One GI, and US Heart & Vascular, and collaborate with biopharma companies to expand access to clinical trials and advance research.
Founded in 2017, Iterative Health has secured significant funding, including a $150 million Series B round in January 2022, indicating strong investor confidence. The company is positioned for growth as an emerging leader in AI-assisted gastroenterology, driven by innovation, strategic partnerships, and active hiring, though public commercial metrics are limited as they evolve towards a services-led clinical research site-network model.

Investors

Who's funded Iterative Health.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.